| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 79.3% F1 (INDELs, average over the 21 replicate pairs as printed) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'Average', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 81.2% F1 (INDELs, tumour WGS_EA_T_1 with normal WGS_EA_N_1) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_EA_T_1 vs WGS_EA_N_1', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 78.5% F1 (INDELs, tumour WGS_FD_T_1 with normal WGS_FD_N_1) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_FD_T_1 vs WGS_FD_N_1', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 77.8% F1 (INDELs, tumour WGS_FD_T_2 with normal WGS_FD_N_2) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_FD_T_2 vs WGS_FD_N_2', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 78.8% F1 (INDELs, tumour WGS_FD_T_3 with normal WGS_FD_N_3) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_FD_T_3 vs WGS_FD_N_3', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 81.4% F1 (INDELs, tumour WGS_IL_T_1 with normal WGS_IL_N_1) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_IL_T_1 vs WGS_IL_N_1', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 79.7% F1 (INDELs, tumour WGS_IL_T_2 with normal WGS_IL_N_2) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_IL_T_2 vs WGS_IL_N_2', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 79.2% F1 (INDELs, tumour WGS_IL_T_3 with normal WGS_IL_N_3) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_IL_T_3 vs WGS_IL_N_3', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 69.5% F1 (INDELs, tumour WGS_LL_T_1 with normal WGS_LL_N_1) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_LL_T_1 vs WGS_LL_N_1', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 78% F1 (INDELs, tumour WGS_NC_T_1 with normal WGS_NC_N_1) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NC_T_1 vs WGS_NC_N_1', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 81.2% F1 (INDELs, tumour WGS_NS_T_1 with normal WGS_NS_N_1) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NS_T_1 vs WGS_NS_N_1', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 77.5% F1 (INDELs, tumour WGS_NS_T_2 with normal WGS_NS_N_2) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NS_T_2 vs WGS_NS_N_2', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 77.5% F1 (INDELs, tumour WGS_NS_T_3 with normal WGS_NS_N_3) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NS_T_3 vs WGS_NS_N_3', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 81.1% F1 (INDELs, tumour WGS_NS_T_4 with normal WGS_NS_N_4) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NS_T_4 vs WGS_NS_N_4', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 78.1% F1 (INDELs, tumour WGS_NS_T_5 with normal WGS_NS_N_5) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NS_T_5 vs WGS_NS_N_5', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 81.3% F1 (INDELs, tumour WGS_NS_T_6 with normal WGS_NS_N_6) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NS_T_6 vs WGS_NS_N_6', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 81.3% F1 (INDELs, tumour WGS_NS_T_7 with normal WGS_NS_N_7) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NS_T_7 vs WGS_NS_N_7', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 76.4% F1 (INDELs, tumour WGS_NS_T_8 with normal WGS_NS_N_8) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NS_T_8 vs WGS_NS_N_8', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 78.6% F1 (INDELs, tumour WGS_NS_T_9 with normal WGS_NS_N_9) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NS_T_9 vs WGS_NS_N_9', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 82.7% F1 (INDELs, tumour WGS_NV_T_1 with normal WGS_NV_N_1) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NV_T_1 vs WGS_NV_N_1', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 82.6% F1 (INDELs, tumour WGS_NV_T_2 with normal WGS_NV_N_2) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NV_T_2 vs WGS_NV_N_2', column 'NeuSomatic DREAM3' |
|---|
| Configuration: NeuSomatic DREAM3 model (Sahraeian et al. 2022) | Protocol: SEQC2 HCC1395 sequencing centre and platform, indel F1 (Sahraeian et al. 2022 Table S2)
Dataset: SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres | 83.6% F1 (INDELs, tumour WGS_NV_T_3 with normal WGS_NV_N_3) percent · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNeuSomatic DREAM3 on SEQC2 HCC1395/HCC1395BL WGS replicate pairs from multiple sequencing centres, INDELs (Sahraeian et al. 2022) somatic-neusomatic-20261010-protocol-sahraeian2022-wgs-indel Aggregation: Not reported Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample; Sahraeian et al. 2022, Additional file 2: Supplementary Tables S1-S10 (13059_2021_2592_MOESM2_ESM.pdf) · Additional file 2 Table S2, INDELs section, row 'WGS_NV_T_3 vs WGS_NV_N_3', column 'NeuSomatic DREAM3' |
|---|